This synopsis summarizes the 2025 ACC/AHA/ACEP/NAEMSP/SCAI clinical guidelines for managing acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients with ACS are at the highest risk for cardiovascular complications both acutely and chronically, which emphasizes the importance of staying up-to-date on the most recent evidence presented in this guideline. With appropriate management, we can improve outcomes both in the hospital and over the long term.”
“In the past, the guidelines were separated into STEMI and non-ST segment elevation and ACS. In this document, we combined both and narrowed the focus to specifically type 1 MI, not type 2 or MI with nonobstructive coronary arteries (MINOCA). MINOCA is covered in the chest pain guidelines. It's been quite a while since the last document and the field moves quickly. There are multiple randomized trials now influencing clinical practice that clinicians are either already incorporating into their practice or are looking to an updated guidelines document to understand how to incorporate those things into their clinical practice.”
“This is the first time since 1999 we have a treatment strategy that reduces mortality in acute cardiogenic shock. This is a very important update.”
Implement unified ACS protocols for type 1 MI now; extends prior separate STEMI and NSTE-ACS guidelines.
This JAMA Clinical Guidelines Synopsis summarizes the 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndrome.
Vohra et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: